Cipla Ltd.
Snapshot View

1031.50 +1.75 ▲0.2%

07 February 2023, 04:01:00 PM
Volume: 19,499

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.cipla.com
Market Cap 83,244.79 Cr.
Enterprise Value(EV) 82,262.92 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 32.69 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 31.56 Trailing Twelve Months Ending 2022-12
Industry PE 32.80 Trailing Twelve Months Ending 2022-12
Book Value / Share 281.14 Trailing Twelve Months Ending 2022-12
Price to Book Value 3.67 Calculated using Price: 1,031.50
Dividend Yield 0.48 Period Ending 2022-03
No. of Shares Subscribed 80.71 Cr. 807,143,930 Shares
FaceValue 2
Company Profile
The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.17%
1 Week
+1.43%
1 Month
-4.18%
3 Month
-8.81%
6 Month
-0.27%
1 Year
+10.49%
2 Year
+21.70%
5 Year
+81.24%
10 Year
+161.77%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 14.89 12.10 12.61 8.72 10.65 10.37 10.09 14.13 13.10
Return on Capital Employed (%) 19.05 15.33 13.24 8.28 10.20 11.94 12.53 17.85 17.24
Return on Assets (%) 10.49 7.85 7.28 4.97 6.52 6.50 6.56 9.95 9.94

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 10,050 10,801 11,516 12,544 14,229 15,012 15,763 18,327 20,842 21,884
Non Curr. Liab. 2,028 2,418 1,407 4,513 4,259 4,646 2,972 1,660 622 117
Curr. Liab. 2,564 3,881 7,776 3,374 3,832 3,772 4,393 4,591 4,913 5,309
Minority Int. 50 180 350 438 352 332 294 259 276 285
Equity & Liab. 14,692 17,281 21,049 20,869 22,673 23,762 23,423 24,837 26,652 27,596
Non Curr. Assets 9,040 9,689 12,208 12,064 11,859 11,335 11,717 11,628 11,925 11,690
Curr. Assets 5,652 7,591 8,841 8,736 10,814 12,425 11,704 13,181 14,711 15,906
Misc. Exp. not W/O
Total Assets 14,692 17,281 21,049 20,869 22,673 23,762 23,423 24,837 26,652 27,596

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 10,173 11,345 13,595 14,394 15,156 16,362 17,132 19,160 21,763 22,274
Other Income 265 166 208 229 358 477 369 270 322 405
Total Income 10,439 11,511 13,803 14,623 15,513 16,839 17,501 19,429 22,085 22,679
Total Expenditure -8,040 -9,184 -11,115 -11,919 -12,329 -13,265 -13,951 -14,911 -17,251 -17,671
PBIDT 2,398 2,327 2,688 2,704 3,184 3,574 3,550 4,518 4,834 5,008
Interest -146 -168 -207 -159 -114 -168 -197 -161 -106 -93
Depreciation -373 -505 -754 -1,323 -1,323 -1,326 -1,175 -1,068 -1,052 -1,116
Taxation -463 -400 -332 -180 -250 -570 -631 -889 -934 -1,052
Exceptional Items -78 -182 -58
PAT 1,417 1,254 1,395 1,042 1,419 1,510 1,547 2,401 2,559 2,689
Minority Interest -16 -48 -23 -29 -6 35 47 16 -30 -44
Share Associate -12 -25 -12 -7 -3 -17 -47 -13 -13 -7
Other Related Items
Consolidated Net Profit 1,388 1,181 1,360 1,006 1,411 1,528 1,547 2,405 2,517 2,638
Adjusted EPS 17 15 17 13 18 19 19 30 31 33

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 1,398 1,563 1,173 1,741 2,382 1,463 1,691 3,068 3,755 3,326
Cash Fr. Inv. -2,063 -1,250 -941 -4,523 -1,310 -854 -1,669 104 -2,387 -1,872
Cash Fr. Finan. 718 -266 165 3,104 -1,326 -385 -349 -2,949 -1,240 -1,600
Net Change 53 48 397 322 -254 223 -326 224 129 -146
Cash & Cash Eqvt 143 176 564 858 610 853 508 742 790 658

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 36.70 36.73 36.72 36.12 36.11 33.63 33.61 33.61 33.61
Public 63.30 63.27 63.28 63.88 63.89 66.37 66.39 66.39 66.39
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Mon, 06 Feb 2023
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
We hereby notify that the Income Tax Department (the Department) conducted a search under the Income Tax Act 1961 at some of our offices and manufacturing units. The Company fully co-operated with the officials during the proceedings and responded to the clarifications and details sought by them. We will continue to provide any further clarification /information that may be required.The business operations of the Company continued as usual and were not impacted due to the search.We will comply with our legal obligation for disclosure from time to time.
Mon, 30 Jan 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We are enclosing herewith copy of the transcript of the Companys Q3 FY23 earnings conference call dated 25th January 2023. The transcript is also available on the Companys website i.e. https://www.cipla.com/sites/default/files/Earnings-Call-Transcript-Q3FY23.pdf .
Wed, 25 Jan 2023
Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended 31St December 2022
The Board of Directors of the Company at its meeting held today i.e. 25th January 2023 has inter-alia approved the unaudited financial results (standalone and consolidated) for the quarter and nine months ended 31st December 2022.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed as follows:

(1) Unaudited financial results (standalone and consolidated) as per Indian Accounting Standards for the
quarter and nine months ended 31st December 2022; and

(2) Limited review report (standalone and consolidated) by Walker Chandiok & Co LLP Statutory Auditor of the Company for the quarter and nine months ended 31st December 2022.

The meeting of the Board of Directors of the Company commenced at 10.30 a.m. (IST) and is still in progress.

Technical Scans View Details >>

Tue, 07 Feb 2023
Higher Delivery Quantity Higher Delivery Quantity
Close Within 52 Week High Zone Close Within 52 Week High Zone
Closing Near 200 SMA Closing Near 200 SMA
CCI Bullish CCI Bullish
Mon, 06 Feb 2023
Closing Above Previous High Closing Above Previous High

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 241,289.12 1,005.65 -1.7%
Dr. Reddy's Laboratories Ltd. 73,968.14 4,441.90 +2.1%
Divi's Laboratories Ltd. 72,982.62 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. 62,084.06 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. 51,953.07 1,533.45 -0.4%
Zydus Lifesciences Ltd. 48,525.07 479.40 +2.0%
Abbott India Ltd. 44,533.86 20,966.50 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 57.29 1,005.65 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.30 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-12 30.45 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 74.00 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.45 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-12 23.54 479.40 +2.0%
Abbott India Ltd. Standalone 2022-09 50.51 20,966.50 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.36 1,005.65 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.36 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-12 5.87 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.38 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.14 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.81 479.40 +2.0%
Abbott India Ltd. Standalone 2022-09 16.41 20,966.50 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,005.65 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 479.40 +2.0%
Abbott India Ltd. Standalone 2022-03 0.00 20,966.50 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,005.65 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 479.40 +2.0%
Abbott India Ltd. Standalone 2022-03 29.95 20,966.50 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,005.65 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 479.40 +2.0%
Abbott India Ltd. Standalone 2022-03 29.95 20,966.50 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,005.65 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 479.40 +2.0%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,966.50 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,005.65 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,441.90 +2.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,749.20 -1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,321.40 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,533.45 -0.4%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 479.40 +2.0%
Abbott India Ltd. Standalone 2022-03 798.70 20,966.50 +0.4%

FAQ's On Cipla Ltd.

What is Cipla share price?

Can I buy Cipla shares now?

What is the Dividend Yield of Cipla?

What is the Market Cap of Cipla?

What are the key metrics to analyse Cipla?

What is the 52 Week High and Low of Cipla?

What is the trend of Cipla share price?